AKT1 and neoplasm: Combination treatment with the PPARγ agonist rosiglitazone and the AKT inhibitor triciribine synergistically inhibited the HCC stem cell-like phenotype and tumor growth in vivo. These findings raise the possibility that the combined administration of rosiglitazone and triciribine could prove to be of therapeutic importance for the clinical treatment of HCC.